SCHEMBL20838409

SCHEMBL20838409

CS(=O)(=O)c1cccc(C(c2ccc(F)cc2)C(O)CN2C(=O)c3ccccc3C2=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.40
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
PTGS2 P35354 2/20 0.38
HSD11B1 P28845 1/20 0.38
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 4/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
CLTC Q00610 1/20 0.36
MEN1 O00255 1/20 0.36
RPS6KA2 Q15349 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19330079 1.00 CASP3 (0.40) CASP3MMP2MMP9PTGS2HSD11B1
SCHEMBL20851037 0.88 CASP3 (0.36) CASP3MMP2MMP9PTGS2HSD11B1
SCHEMBL19329978 0.84 ALDH1A1 (0.48) CASP3MMP2MMP9KMT2AALDH1A1
SCHEMBL20838349 0.84 ALDH1A1 (0.48) CASP3MMP2MMP9KMT2AALDH1A1
SCHEMBL20838423 0.82 MEN1 (0.46) CASP3MMP2MMP9KMT2AALDH1A1
SCHEMBL29881198 0.82 MEN1 (0.46) CASP3MMP2MMP9KMT2AALDH1A1
SCHEMBL20838424 0.82 MEN1 (0.46) CASP3MMP2MMP9KMT2AALDH1A1
SCHEMBL19346594 0.82 MAPT (0.44) CASP3KMT2AALDH1A1POLBPKM
SCHEMBL22723198 0.82 MAPT (0.44) CASP3KMT2AALDH1A1POLBPKM
SCHEMBL20838412 0.79 PTGDR2 (0.43) PTGS2HSD11B1ALDH1A1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453677-B2 Tricyclic compounds useful to treat orthomyxovirus infections NOVARTIS AG (CH) 2022-09-27 US disclosed
EP-3426656-B1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2021-05-12 EP disclosed
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections NOVARTIS AG (CH) 2020-12-08 US disclosed
US-20200347072-A1 Tricyclic Compounds Useful to Treat Orthomyxovirus Infections NOVARTIS AG (CH) 2020-11-05 US disclosed
US-20190092780-A1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2019-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections ZC3HAV1, OTC, THOP1 CASP3 3073/4885MMP2 931/4885MMP9 3731/4885
US-20200347072-A1 Tricyclic Compounds Useful to Treat Orthomyxovirus Infections ZC3HAV1, OTC, THOP1 CASP3 2751/4885MMP2 883/4885MMP9 3738/4885
US-11453677-B2 Tricyclic compounds useful to treat orthomyxovirus infections ZC3HAV1, OTC, THOP1 CASP3 2751/4885MMP2 883/4885MMP9 3738/4885
US-20190092780-A1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS ZC3HAV1, OTC, THOP1 CASP3 3073/4885MMP2 931/4885MMP9 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.